Search

The article discusses the routine testing and reporting of piperacillin/tazobactam susceptibility in Elizabethkingia species, which are increasingly prevalent pathogens in Asia. The study found that there is variability in the results of different susceptibility assays, leading to inconsistent reporting of susceptibility rates. In addition, the presence of a specific gene, blaB, in Elizabethkingia species was found to increase resistance to piperacillin/tazobactam and reduce its efficacy in vivo. The authors suggest that routine testing and reporting of piperacillin/tazobactam susceptibility in Elizabethkingia species may not be informative for treatment decisions. [Extracted from the article]

Summary: Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Western countries but very rare in Asia. Peripheral blood or bone marrow mononuclear cells obtained at initial diagnosis from 194 patients with CLL were analysed to determine the ethnic difference in genetic abnormalities. Mutated IGHV was detected in 71·2% of Taiwanese CLL and IGHV3‐23 was the most frequently used gene. Stereotyped BCR was present in 18·3% with subset 8 being the most frequent. All cases with subset 8 belonged to IGHV 4‐39 and were exclusively associated with un‐mutated IGHV and poor outcome. Mutation frequencies of SF3B1 (9·7%), NOTCH1 (8·6%), BIRC3 (1·1%), ATM (16·9%) or TP53 (8·1%), and frequencies of cytogenetic abnormalities including trisomy 12 (18·6%), del(17p) (10·4%), del(13q) (43·7%) and IGH translocation (10·1%) were comparable to those reported from Western countries, except del(11q) (6·9%) which was lower in our patients. Patients with un‐mutated IGHV, subset 8, disrupted TP53, trisomy 12, and SF3B1 mutations had a worse outcome compared to patients without these mutations. In conclusion, IGHV3‐23 usage, stereotyped subset 8 and lower frequency of del(11q) show an ethnicity‐dependent association in Taiwanese CLL patients. [ABSTRACT FROM AUTHOR]

We previously showed that Month 13 50% plaque reduction neutralization test (PRNT50) neutralizing antibody (nAb) titers against dengue virus (DENV) correlated with vaccine efficacy (VE) of CYD-TDV against symptomatic, virologically-confirmed dengue (VCD) in the CYD14 and CYD15 Phase 3 trials. While PRNT is the gold standard nAb assay, it is time-consuming and costly. We developed a next-generation high-throughput microneutralization (MN) assay and assessed its suitability for immune-correlates analyses and immuno-bridging applications. We analyzed MN and PRNT50 titers measured at baseline and Month 13 in a randomly sampled immunogenicity subset, and at Month 13 in nearly all VCD cases through Month 25. For each serotype, MN and PRNT50 titers showed high correlations, at both baseline and Month 13, with MN yielding a higher frequency of baseline-seronegatives. For both assays, Month 13 titer correlated inversely with VCD risk. Like PRNT50, high Month 13 MN titers were associated with high VE, and estimated VE increased with average Month 13 MN titer. We also studied each assay as a valid surrogate endpoint based on the Prentice criteria, which supported each assay as a valid surrogate for DENV-1 but only partially valid for DENV-2, -3, and -4. In addition, we applied Super-Learner to assess how well demographic, Month 13 MN, and/or Month 13 PRNT50 titers could predict Month 13–25 VCD outcome status; prediction was best when using demographic, MN, and PRNT50 information. We conclude that Month 13 MN titer performs comparably to Month 13 PRNT50 titer as a correlate of risk, correlate of vaccine efficacy, and surrogate endpoint. The MN assay could potentially be used to assess nAb titers in immunogenicity studies, immune-correlates studies, and immuno-bridging applications. Additional research would be needed for assessing the utility of MN titer in correlates analyses of other DENV endpoints and over longer follow-up periods. [ABSTRACT FROM AUTHOR]

The long persistent rainfall (LPR) over the northern part of China has a great impact on its society and economics. This study investigates the decadal shift of the regional‐mean LPR frequency over the northern part of China (LPR frequency) from 1971 to 2014 and the associated ocean conditions. The LPR frequency has experienced a significant decadal shift around 1996, with an enhanced (reduced) anomaly before (after) 1996, which is closely associated with a meridional tri‐pole sea surface temperature (SST) anomaly over the central Pacific, a La Niña‐like anomaly for the pre‐1996 epoch (1971–1996) and an obvious warming over the south Indian Ocean and the western part of south Pacific Ocean in the post‐1996 epoch (1997–2014). In the pre‐1996 epoch, associated with the typical SSTs, the ascent motion with increasing humidity anomalies are over the northern part of China. Meanwhile, high (low) pressure anomalies are over western Asia and East Asia (Europe and central Asia), which resembles as the positive phase of the Silk Road pattern (SRP). It would be associated with the polewards shift of the East Asian jet stream (EAJS) and therefore result in the northwards shift of the rain belt and benefit the occurrence of the LPR. In the post‐1996 epoch, associated with the warming over the specific south oceans, a descend anomaly dominates over the northern part of China, as well as the resembled negative phase of the SRP over mid‐high latitudes and equatorwards shift of the EAJS. These would suppress the rainfall over the northern part of China and reduce the LPR frequency over there after 1996. [ABSTRACT FROM AUTHOR]

Background: In the CYD14 and CYD15 Phase 3 trials of the CYD-TDV dengue vaccine, estimated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue (VCD) occurring between months 13 and 25 was 56.5% and 60.8%, respectively.Methods: Neutralizing antibody titers to the 4 dengue serotypes in the CYD-TDV vaccine insert were measured at month 13 in a randomly sampled immunogenicity subcohort and in all VCD cases through month 25 (2848 vaccine, 1574 placebo) and studied for their association with VCD and with the level of VE to prevent VCD.Results: For each trial and serotype, vaccinees with higher month 13 titer to the serotype had significantly lower risk of VCD with that serotype (hazard ratios, 0.19-0.43 per 10-fold increase). Moreover, for each trial, vaccinees with higher month 13 average titer to the 4 serotypes had significantly higher VE against VCD of any serotype (P < .001).Conclusions: Neutralizing antibody titers postdose 3 correlate with CYD-TDV VE to prevent dengue. High titers associate with high VE for all serotypes, baseline serostatus groups, age groups, and both trials. However, lowest titers do not fully correspond to zero VE, indicating that other factors influence VE. [ABSTRACT FROM AUTHOR]